Clinical Trial Update: Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

An update on an anti-FLT3 CAR T-cell therapy being evaluated in FLT3-positive relapsed/refractory acute myeloid leukemia across Phase 1 and Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-FLT3 CAR T-cell therapy

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN